Durvalumab not cost effective for first-line treatment of advanced SCLC

    This is a preview of subscription content, access via your institution.

    Notes

    1. 1.

      Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer

    Reference

    1. Tong YH, et al. Cost-effectiveness analysis of durvalumab plus etoposide: platinum in the first-line therapy of extensive stage small-cell lung cancer from the Chinese payers' perspective. Tumori : 29 Jan 2021. Available from: URL: http://doi.org/10.1177/0300891620985309

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Durvalumab not cost effective for first-line treatment of advanced SCLC. PharmacoEcon Outcomes News 872, 13 (2021). https://doi.org/10.1007/s40274-021-7486-5

    Download citation